Transfer-pricing treatment of ITeS margins excludes pass-through tax recoveries and separate delayed-receivables interest after working-capital adjust...
Capacity-utilisation adjustments under TNMM can neutralise substantiated COVID-related idle costs where underutilisation materially affects profitabil...
TNMM functional comparability requires excluding rice manufacturers from a pure Basmati rice trader's benchmark and recognising operating export recei...
Working-capital adjustment subsumes delayed-receivable effects in TNMM benchmarking of captive software-development services, avoiding separate notion...
Transfer-pricing comparability requires exclusion of financially illogical super-profit comparables and correction of unsupported annual-report and ma...
Charitable character assessment preserves Section 80G approval despite inclusive spiritual teachings and incidental religious expenditure within the s...
Penalty proceedings for cash-loan acceptance require assessment proceedings and recorded Assessing Officer satisfaction; absent these, the proceedings...
Page of 4828
Press 'Enter' after typing page number.
161 to 180 of 96556 Results
❮
❯
❯❯
0 / 200
Expand Note
Add to Folder
No Folders have been created
+
Are you sure you want to delete "My most important" ?
DGFT has withdrawn Para 2.76 of Handbook of Procedures 2023 (formerly Para 2.90A of HBP 2015-2020) regarding Track and Trace system for export of drug formulations, exercising powers under Paragraphs 1.03 and 2.04 of Foreign Trade Policy 2023. The responsibility for implementing authentication systems for exported drug formulations now transfers to Ministry of Health and Family Welfare, to be administered under Drug Rules 1945. The withdrawal takes immediate effect, marking a significant shift in regulatory oversight of pharmaceutical exports from trade authorities to healthcare regulators.
DGFT has withdrawn Para 2.76 of Handbook of Procedures 2023 (formerly Para 2.90A of HBP 2015-2020) regarding Track and Trace system for export of drug formulations, exercising powers under Paragraphs 1.03 and 2.04 of Foreign Trade Policy 2023. The responsibility for implementing authentication systems for exported drug formulations now transfers to Ministry of Health and Family Welfare, to be administered under Drug Rules 1945. The withdrawal takes immediate effect, marking a significant shift in regulatory oversight of pharmaceutical exports from trade authorities to healthcare regulators.
Note: It is a system-generated summary and is for quick reference only.